Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2022 May 15

PMID 35570253

Authors

Urs Duthaler

Fabio Bachmann

Claudia Suenderhauf

Tanja Grandinetti

Florian Pfefferkorn

Manuel Haschke

Petr Hruz

Jamal Bouitbir

Stephan Krahenbuhl

Affiliations

Soon will be listed here.

Abstract

Background: Activities of hepatic cytochrome P450 enzymes (CYPs) are relevant for hepatic clearance of drugs and known to be decreased in patients with liver cirrhosis. Several studies have reported the effect of liver cirrhosis on CYP activity, but the results are partially conflicting and for some CYPs lacking.

Objective: In this study, we aimed to investigate the CYP activity in patients with liver cirrhosis with different Child stages (A-C) using the Basel phenotyping cocktail approach.

Methods: We assessed the pharmacokinetics of the six compounds and their CYP-specific metabolites of the Basel phenotyping cocktail (CYP1A2: caffeine, CYP2B6: efavirenz, CYP2C9: flurbiprofen, CYP2C19: omeprazole, CYP2D6: metoprolol, CYP3A: midazolam) in patients with liver cirrhosis (n = 16 Child A cirrhosis, n = 15 Child B cirrhosis, n = 5 Child C cirrhosis) and matched control subjects (n = 12).

Results: While liver cirrhosis only marginally affected the pharmacokinetics of the low to moderate extraction drugs efavirenz and flurbiprofen, the elimination rate of caffeine was reduced by 51% in patients with Child C cirrhosis. For the moderate to high extraction drugs omeprazole, metoprolol, and midazolam, liver cirrhosis decreased the elimination rate by 75%, 37%, and 60%, respectively, increased exposure, and decreased the apparent systemic clearance (clearance/bioavailability). In patients with Child C cirrhosis, the metabolic ratio (ratio of the area under the plasma concentration-time curve from 0 to 24 h of the metabolite to the parent compound), a marker for CYP activity, decreased by 66%, 47%, 92%, 73%, and 43% for paraxanthine/caffeine (CYP1A2), 8-hydroxyefavirenz/efavirenz (CYP2B6), 5-hydroxyomeprazole/omeprazole (CYP2C19), α-hydroxymetoprolol/metoprolol (CYP2D6), and 1'-hydroxymidazolam/midazolam (CYP3A), respectively. In comparison, the metabolic ratio 4-hydroxyflurbiprofen/flurbiprofen (CYP2C9) remained unchanged.

Conclusions: Liver cirrhosis affects the activity of CYP isoforms differently. This variability must be considered for dose adjustment of drugs in patients with liver cirrhosis.

Clinical Trial Registration: NCT03337945.

Citing Articles

Improving Individualized Salbutamol Treatment: A Population Pharmacokinetic Model for Oral Salbutamol in Virtual Patients.

Marques L, Vale N Pharmaceutics. 2025; 17(1.

PMID: 39861686 PMC: 11768577. DOI: 10.3390/pharmaceutics17010039.

New Insights Into Hepatic Impairment (HI) Trials.

Haertter S, Lobmeyer M, Ferslew B, Mitra P, Arnhold T Clin Transl Sci. 2025; 18(1):e70130.

PMID: 39797487 PMC: 11724149. DOI: 10.1111/cts.70130.

Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review.

Abdelmonem B, Abdelaal N, Anwer E, Rashwan A, Hussein M, Ahmed Y Biomedicines. 2024; 12(7).

PMID: 39062040 PMC: 11275228. DOI: 10.3390/biomedicines12071467.

Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function.

Yin W, Mitra P, Copalu V, Marbury T, Rondon J, Lawitz E Pharmacol Res Perspect. 2024; 12(4):e1213.

PMID: 38993008 PMC: 11239955. DOI: 10.1002/prp2.1213.

Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects.

Luo X, Zhang Z, Mu R, Hu G, Liu L, Liu X Pharmaceutics. 2024; 16(2).

PMID: 38399287 PMC: 10893190. DOI: 10.3390/pharmaceutics16020234.

References

Franz C, Egger S, Born C, Ratz Bravo A, Krahenbuhl S . Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2011; 68(2):179-88. DOI: 10.1007/s00228-011-1105-5. View

Lucena M, Andrade R, Tognoni G, Hidalgo R, de la Cuesta F . Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002; 58(6):435-40. DOI: 10.1007/s00228-002-0474-1. View

Lucena M, Andrade R, Tognoni G, Hidalgo R, de la Cuesta F . Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2003; 59(1):71-6. DOI: 10.1007/s00228-003-0586-2. View

Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S . Dose adjustment in patients with liver disease. Drug Saf. 2005; 28(6):529-45. DOI: 10.2165/00002018-200528060-00005. View

Johnson T, Boussery K, Rowland-Yeo K, Tucker G, Rostami-Hodjegan A . A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010; 49(3):189-206. DOI: 10.2165/11318160-000000000-00000. View

Taegtmeyer A, Haschke M, Tchambaz L, Buylaert M, Tschopl M, Beuers U . A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. PLoS One. 2014; 9(6):e97885. PMC: 4048194. DOI: 10.1371/journal.pone.0097885. View

Franz C, Hildbrand C, Born C, Egger S, Ratz Bravo A, Krahenbuhl S . Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. Eur J Clin Pharmacol. 2013; 69(8):1565-73. DOI: 10.1007/s00228-013-1502-z. View

Berger B, Dingemanse J, Sabattini G, Delahaye S, Duthaler U, Muehlan C . Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clin Pharmacokinet. 2021; 60(10):1349-1360. DOI: 10.1007/s40262-021-01028-8. View

Nebert D, Russell D . Clinical importance of the cytochromes P450. Lancet. 2002; 360(9340):1155-62. DOI: 10.1016/S0140-6736(02)11203-7. View

10.

Derungs A, Donzelli M, Berger B, Noppen C, Krahenbuhl S, Haschke M . Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study. Clin Pharmacokinet. 2015; 55(1):79-91. PMC: 4712254. DOI: 10.1007/s40262-015-0294-y. View

11.

Donzelli M, Derungs A, Serratore M, Noppen C, Nezic L, Krahenbuhl S . The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokinet. 2013; 53(3):271-282. DOI: 10.1007/s40262-013-0115-0. View

12.

Suenderhauf C, Berger B, Puchkov M, Schmid Y, Muller S, Huwyler J . Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults. Br J Clin Pharmacol. 2019; 86(2):352-361. PMC: 7015750. DOI: 10.1111/bcp.14157. View

13.

Camblin M, Berger B, Haschke M, Krahenbuhl S, Huwyler J, Puchkov M . CombiCap: A novel drug formulation for the basel phenotyping cocktail. Int J Pharm. 2016; 512(1):253-261. DOI: 10.1016/j.ijpharm.2016.08.043. View

14.

Frye R, Zgheib N, Matzke G, Chaves-Gnecco D, Rabinovitz M, Shaikh O . Liver disease selectively modulates cytochrome P450--mediated metabolism. Clin Pharmacol Ther. 2006; 80(3):235-45. DOI: 10.1016/j.clpt.2006.05.006. View

15.

KRAUL H, Truckenbrodt J, Huster A, Topfer R, Hoffmann A . Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity. Eur J Clin Pharmacol. 1991; 41(5):475-80. DOI: 10.1007/BF00626373. View

16.

Renner E, Wietholtz H, Huguenin P, Arnaud M, Preisig R . Caffeine: a model compound for measuring liver function. Hepatology. 1984; 4(1):38-46. DOI: 10.1002/hep.1840040107. View

17.

Adedoyin A, Arns P, Richards W, Wilkinson G, Branch R . Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther. 1998; 64(1):8-17. DOI: 10.1016/S0009-9236(98)90017-0. View

18.

Ohnishi A, Murakami S, Akizuki S, Mochizuki J, Echizen H, Takagi I . In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. J Clin Pharmacol. 2005; 45(11):1221-9. DOI: 10.1177/0091270005280787. View

19.

Larrey D, Babany G, Tinel M, Freneaux E, Amouyal G, Habersetzer F . Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients. Br J Clin Pharmacol. 1989; 28(3):297-304. PMC: 1379948. DOI: 10.1111/j.1365-2125.1989.tb05430.x. View

20.

Albarmawi A, Czock D, Gauss A, Ehehalt R, Lorenzo Bermejo J, Burhenne J . CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol. 2013; 77(1):160-9. PMC: 3895357. DOI: 10.1111/bcp.12182. View